

A non-interventional study to assess the long-term safety and efficacy of osilodrostat in patients with endogenous Cushing's syndrome (LINC 6)

First published: 13/07/2022

Last updated: 25/09/2025

Study

Ongoing

Administrative details

EU PAS number

EUPAS46496

Study ID

46497

DARWIN EU® study


No

Study countries

 France

 Germany

 Italy

 Netherlands

 United States

Study status

Ongoing

Contact details

Study institution contact

Mario MALDONADO maldonado.m@recordati.com

Study contact

maldonado.m@recordati.com

Primary lead investigator

Mario MALDONADO

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 22/12/2021

Study start date

Actual: 13/06/2022

Date of final study report

Planned: 31/12/2027

Sources of funding

More details on funding

Recordati AG

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Study type:

Non-interventional study

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes